T-cell tumor necrosis factor-α receptor binding in myasthenic patients

[1]  L. Murri,et al.  T-cell interleukin-6 receptor binding in patients with myasthenia gravis , 1998, Journal of the Neurological Sciences.

[2]  M. Castagna,et al.  T-cell tumour necrosis factor-α receptor binding in demented patients , 1997, Journal of Neurology.

[3]  H. Link,et al.  Cytokines and the pathogenesis of myasthenia gravis , 1997, Muscle & nerve.

[4]  P. Bongioanni,et al.  T‐cell tumor necrosis factor‐α receptor binding in patients with multiple sclerosis , 1997, Neurology.

[5]  A. Pinchera,et al.  Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. , 1997, The Journal of clinical endocrinology and metabolism.

[6]  R. Pirskanen,et al.  Tumor necrosis factor-α, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis , 1996, Journal of Neuroimmunology.

[7]  R. Ransohoff,et al.  Cytokines and the CNS , 1996 .

[8]  N. Yanagisawa,et al.  Increased levels of soluble tumor necrosis factor receptor in patients with multiple sclerosis and HTLV-1-associated myelopathy , 1994, Journal of Neuroimmunology.

[9]  L. Tartaglia,et al.  Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. , 1993, Journal of immunology.

[10]  R. Mantegazza,et al.  Immune activation in myasthenia gravis: Soluble interleukin-2 receptor, interferon-γ and tumor necrosis factor-α levels in patients' serum , 1993, Journal of Neuroimmunology.

[11]  O. Blin,et al.  Pharmacological basis of immunotherapy in autoimmune diseases. , 1993, Clinical neuropharmacology.

[12]  F. Sánchez‐Madrid,et al.  Regulation of tumor necrosis factor (TNF)‐α synthesis and TNF receptors expression in T lymphocytes through the CD2 activation pathway , 1992, European journal of immunology.

[13]  C. Ware,et al.  Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. , 1991, Journal of immunology.

[14]  S. Lowry,et al.  Tumor necrosis factor-α , 1991 .

[15]  T. Gatanaga,et al.  Enhancement of lymphokine-activated T killer cell tumor necrosis factor receptor mRNA transcription, tumor necrosis factor receptor membrane expression, and tumor necrosis factor/lymphotoxin release by IL-1 beta, IL-4, and IL-6 in vitro. , 1991, Journal of immunology.

[16]  R. Gentz,et al.  Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. , 1990, Cytokine.

[17]  J. Newsom-Davis,et al.  Autoimmunity in Neuromuscular Disease , 1988, Annals of the New York Academy of Sciences.

[18]  J. Dipersio,et al.  Tumor necrosis factor: receptors on hematopoietic cells. , 1987, Blood.

[19]  P. Scheurich,et al.  Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. , 1987, Journal of immunology.

[20]  R. Hohlfeld,et al.  Myasthenia gravis , 1983, Neurology.

[21]  Nicos Nicola,et al.  Guidebook to cytokines and their receptors , 1994 .

[22]  R. Smith,et al.  Characterization of TNF receptors. , 1992, Immunology series.

[23]  B. Aggarwal,et al.  Tumor necrosis factors. Structure, function, and mechanism of action. , 1992, Immunology series.